Neurizon inks $1.5M loan against R&D Tax Rebate
Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
IFT | Ann: Ongoing Disclosure Notices - Directors and Senior Manager | 25/07/25 | 0 | 93 | |||
|
|||||||
IFT | Ann: Infratil Limited's Notice of Meeting and Proxy Form | 21/07/25 | 0 | 136 | |||
|
|||||||
IFT | Ann: Infratil to be added to S&P / ASX200 Index | 16/07/25 | 0 | 167 | |||
|
|||||||
IFT | Ann: Ongoing Disclosure Notice - J Boyes | 14/07/25 | 0 | 120 | |||
|
|||||||
IFT | Ann: Infratil Newsletter - Impacts of the One Big Beautiful Bill | 09/07/25 | 0 | 131 | |||
|
|||||||
IFT | Ann: Ongoing Disclosure Notice - J Boyes | 07/07/25 | 0 | 147 | |||
|
|||||||
IFT | Ann: CDC Independent Valuation - 30 June 2025 | 04/07/25 | 0 | 150 | |||
|
|||||||
IFT | Ann: ASX Appendix 2A - Dividend Reinvestment Plan | 02/07/25 | 0 | 117 | |||
|
See All Discussions